Bertin Pharma and INDIGO Biosciences Sign Agreement for Distributing Nuclear Receptor Assay Kits in Europe
Over 40 product references to assay nuclear receptors are now available for European researchers during their work in drug discovery and toxicology. These innovative tools are used for profiling compounds in research areas such as metabolic disorders, cardiovascular disease, or even endocrinology.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161114006168/en/
Innovative products to reduce time, cost and risk in drug discovery process
INDIGO Biosciences , leader in Nuclear Receptor Research, provides the world’s largest portfolio of Nuclear Receptor Assay kits using luciferase reporter technology. Those kits are all-inclusive, cell-based, robust, and ready to use for either screening small numbers of test compounds or HTS application.
Expansion to Europe
With a fast-growing business in the USA, INDIGO Biosciences wishes to benefit from increased European exposure to capture new market shares.
Bertin Pharma is one of the major European players for the supply of reagents and assay kits dedicated to the research and development for the pharmaceutical, cosmetic and food industries. Bertin Pharma has marketed biological reagent ranges for over 25 years. Its long R&D experience combined with its International distributor channels enable to deliver life science tools on time and to support customers throughout their experimentation.
Bertin Pharma completes, with this new range of Nuclear Receptor Assay kits, its existing ranges of biomarker assays applied to his expertise areas that are metabolic syndrome, hypertension or even oncology.
“It has been a real honor to be introduced to Fred and his company and we rapidly found a lot of complementarity in our business. The Nuclear Assay range perfectly fit with our customer’s needs, and will empower our commercial activity.” Said Patrick Vitaux, Bioreagent Dpt Manager – Bertin Pharma
“We are pleased to have reached an agreement with Bertin Pharma to expand our distribution network in Europe. We look forward to working with Patrick and his team to bring INDIGO’s assay portfolio to their customers throughout the region.” Fred Marroni, CEO – INDIGO Biosciences
About INDIGO Biosciences
About Bertin Pharma
Fred Marroni (814)234-1919
Frédérique Vigezzi - Gootenberg, +33 (0)143 59 2984
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CHINA-HI-TECH-FAIR15.11.2018 03:02 | pressemeddelelse
Highlights of China’s No. 1 High-Tech Fair CHTF 2018
CA-NEXON-AMERICA-INC14.11.2018 22:02 | pressemeddelelse
MapleStory Prepares for Epic Battle Against the Black Mage in Gathering of Heroes Event
TX-SPINALCYTE14.11.2018 21:09 | pressemeddelelse
SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection
FONDATION-IPSEN14.11.2018 17:57 | pressemeddelelse
Raising Awareness about Early Onset Dementia: “Don’t Leave me now”, Written by Brian Daniels
HCL-TECHNOLOGIES14.11.2018 17:46 | pressemeddelelse
HCL Technologies Celebrates 10 Years of Success in the Nordics
PA-ROCKWELL-AUTOMATION14.11.2018 17:37 | pressemeddelelse
The Next Industrial Transformation is Here: Rockwell Automation is Helping Businesses Prepare to Succeed at Automation Fair 2018
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum